Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6
Journal of Viral Hepatitis May 24, 2019
Lawitz E, et al. - Given the suboptimal effectiveness of the two-drug combination of ruzasvir 60 mg plus uprifosbuvir 450 mg in certain hepatitis C virus (HCV) genotypes in a phase 3 clinical trial, researchers examined rusasvir in combination with uprifosbuvir given at a higher dose for effectiveness and safety. Treatment-naive or interferon (with or without ribavirin)–experienced patients with or without compensated cirrhosis were administered ruzasvir 180 mg plus uprifosbuvir 450 mg once daily for 12 weeks. Outcomes revealed the high efficacy of the two-drug combination of ruzasvir 180 mg plus uprifosbuvir 450 mg for 12 weeks in participants infected with HCV GT1, GT2, GT4, GT5, and GT6, but a lower efficacy in GT3-infected persons. The regimen was considered to be well-tolerated.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries